구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | autologous anti-BCMA chimeric antigen receptor T cells (autologous anti-BCMA chimeric antigen receptor T cells) Poseida Therapeutics, Inc.·BCMA 47 trials |
|---|---|
Overview Program | autologous anti-BCMA chimeric antigen receptor T cells |
Overview Company | Poseida Therapeutics, Inc. |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | ITP |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral vectors (LVV) encoding chimeric antigen receptors (CARs) were constructed with |
MoA Mechanism | targeting B-cell maturation antigen |
MoA Biomarker | BCMA) expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Preclinical analyses reveal a strong correlation between CD8 + T SCM phenotype and in vivo potency in mouse xenograft models. |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (40%) and anemia (13 |
Toxicology CRS | 21.2% |
Clinical Safety signal | thrombocytopenia (40%) and anemia (13 |
Clinical Selected reported efficacy | 74.5% |
Clinical Result source | ClinicalTrials.gov NCT03361748 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03361748 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | autologous anti-BCMA chimeric antigen receptor T cells (autologous anti-BCMA chimeric antigen receptor T cells) Poseida Therapeutics, Inc.·BCMA 47 trials |
|---|---|
Overview Program | autologous anti-BCMA chimeric antigen receptor T cells |
Overview Company | Poseida Therapeutics, Inc. |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | ITP |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral vectors (LVV) encoding chimeric antigen receptors (CARs) were constructed with |
MoA Mechanism | targeting B-cell maturation antigen |
MoA Biomarker | BCMA) expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Preclinical analyses reveal a strong correlation between CD8 + T SCM phenotype and in vivo potency in mouse xenograft models. |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (40%) and anemia (13 |
Toxicology CRS | 21.2% |
Clinical Safety signal | thrombocytopenia (40%) and anemia (13 |
Clinical Selected reported efficacy | 74.5% |
Clinical Result source | ClinicalTrials.gov NCT03361748 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03361748 |
추천 비교
추천 비교